Navigation Links
AquaLiv Technologies Subsidiary AquaLiv, Inc. Discusses Registration In Kenya Concerning Its HIV/AIDS Treatment
Date:10/31/2011

SEATTLE, Oct. 31, 2011 /PRNewswire/ -- AquaLiv Technologies (OTCBB: AQLV) subsidiary, AquaLiv, Inc., discusses alternative medicine registration in Kenya for their NatuRx™ HIV/AIDS treatment.

The company previously announced that Kenyan officials recommend they register NatuRx™ HIV/AIDS as an alternative medicine treatment and that approval could be granted within 30-60 days.

"The process isn't quite as simple as it was explained to us," stated AquaLiv CEO, Craig Hoffman. "It isn't just the treatment that is being registered. Registration also requires completed retail packaging and inspection of a manufacturing facility that complies with cGMP (Current Good Manufacturing Practices) regulation. We wanted to simply get approval for the treatment, but that just isn't possible without the manufacturing component in place."

Mr. Hoffman continued, "We are looking for a manufacturing partner that could eventually supply the treatment to all African countries and we have identified some candidates in both Kenya and India. The big question for us right now is do we sign on with a partner capable of manufacturing our treatment as a liquid solution, as we do now in our laboratory, or should we wait until we have modified the treatment to be delivered in tablet form. We're closer than ever to being able to deliver all NatuRx™ treatments in tablet form and we think we will know definitively before the end of our planned clinical trial, which is when we would actually begin sales of the product."

The company further explained that tablets are more economical to distribute and will require fewer manufacturing partners overall.

"We're confident we will have the manufacturing issues worked out before the end of the trial," added Bill Wright, CEO of AquaLiv Technologies. "However, we communicated to our investors that an alternative medicine registration could be granted around this time and felt it was important to give investors an update."

Based on AquaLiv's patented BioT™ Bioinformation Technology, NatuRx™ formulations utilize novel wave-based information composites in lieu of molecules for treatment.

For more information about AquaLiv, visit their website: http://www.aqualiv.net

About AquaLiv Technologies, Inc.:

AquaLiv Technologies, Inc., through its subsidiaries, offers unique solutions and applications for a variety of industries and emerging technologies.

AquaLiv, Inc. is a life sciences research and development company creating novel products for numerous industries. The company's patented technology alters the behavior of organisms, including plants and humans, without chemical interaction. From increased crop yields to drug-free medicine, AquaLiv is providing innovative, ingredient-free solutions to the world's largest problems. To learn more about AquaLiv, please visit: www.aqualiv.net.

Safe Harbor: Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact:
AquaLiv Technologies, Inc.
360-536-4220


'/>"/>
SOURCE AquaLiv Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Future of GPCRs in Drug Discovery: Novel technologies, leading companies, and opportunities for target expansion
2. Connectyx Technologies to Host Teleconference on Third Quarter Financial Results on Tuesday November 15, 2011
3. Life Technologies Signs Agreement with GlaxoSmithKline Biologicals S.A., Seeking Expanded Use of Platform Technologies into Companion Diagnostics
4. China Medical Technologies Recently Received Approximately 2,200,000 of its ADSs from Two Banks which Borrowed the ADSs in Connection With the Issuance of the Companys Convertible Notes in August 2008
5. Hologic to Host Special Tomosynthesis Symposium and Feature the Latest in Womens Health Technologies at the Journees Francaises de Radiologie (JFR)
6. SPX to Acquire e&e, a Global Supplier of Extraction, Evaporation, Vacuum and Freeze Drying Technologies
7. MedClean Technologies Partners With Triumvirate Environmental
8. goBalto Raises Series A Financing to Advance Cloud-based Health Technologies
9. New Clinical Studies Presented at the American Society of Anesthesiologists Annual Meeting Show Benefits of Masimo Noninvasive Technologies: SpHb, PVI, RRa, and SEDLine
10. Flow Cytometry: Products, Technologies and Global Markets
11. Ion Torrent CEO Jonathan Rothberg, Life Technologies Recognized by Wall Street Journal Technology Innovation Awards for the Ion Personal Genome Machine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to the latest ... Market Study on Multiplex Detection Immunoassay: North America to ... global multiplex detection immunoassay market is expected to witness a CAGR ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
(Date:12/7/2016)... 2016 The global  blood ... of USD 3.9 billion by 2024, based on ... The growth of the market is attributed to ... advancements by the market players. Demand for blood ... donation, rising awareness about transfusion-transmitted diseases, and technological ...
(Date:12/6/2016)... 6, 2016  Alopexx Oncology, LLC announced data from ... fusion protein (immunocytokine) composed of interleukin-2 and a CD20-targeting ... on B cells as Rituxan and maintains the activities ... also involved in tumor targeting, engagement of the immune ... results of the study (abstract #95954) were presented at ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending ... the unique opportunity to get hands-on experience in an emergency medical simulation, When ... experience to gain invaluable, real-life medical skills that are critical success in a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand ... at the Icahn School of Medicine at Mount Sinai has found. The study ... young children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
(Date:12/7/2016)... ... 2016 , ... Levels of a protein in the blood associated with heart ... in the journal Radiology. , Heart disease and brain disease exact a major burden ... aging population. Damage to both organs often occurs at a subclinical stage, or before ...
Breaking Medicine News(10 mins):